PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature
leading to elevated pulmonary pressure and right ventricular (RV) dysfunction with heart
failure. Measures of RV function are better predictors of mortality and long term outcomes
than pulmonary vascular resistance. The interaction between RV function and the pulmonary
circulation is not fully understood, but increased after load appears insufficient to explain
right heart failure. Yet, all approved PAH therapies target vasodilation of the pulmonary
vasculature to lower pressures
Phase:
N/A
Details
Lead Sponsor:
The Cleveland Clinic
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)